Prevalidation of Salivary Biomarkers for Oral Cancer Detection

Background: Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three...

Full description

Saved in:
Bibliographic Details
Published inCancer epidemiology, biomarkers & prevention Vol. 21; no. 4; pp. 664 - 672
Main Authors Elashoff, David, Zhou, Hui, Reiss, Jean, Wang, Jianghua, Xiao, Hua, Henson, Bradley, Hu, Shen, Arellano, Martha, Sinha, Uttam, Le, Anh, Messadi, Diana, Wang, Marilene, Nabili, Vishad, Lingen, Mark, Morris, Darly, Randolph, Timothy, Feng, Ziding, Akin, David, Kastratovic, Dragana A., Chia, David, Abemayor, Elliot, Wong, David T.W.
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 01.04.2012
Subjects
Online AccessGet full text
ISSN1055-9965
1538-7755
1538-7755
DOI10.1158/1055-9965.EPI-11-1093

Cover

Abstract Background: Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL). Methods: Three hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL. Results: Expression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts. Conclusions: The validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies. Impact: Salivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects. Cancer Epidemiol Biomarkers Prev; 21(4); 664–72. ©2012 AACR.
AbstractList Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL).BACKGROUNDOral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL).Three hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL.METHODSThree hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL.Expression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts.RESULTSExpression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts.The validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies.CONCLUSIONSThe validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies.Salivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects.IMPACTSalivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects.
Background: Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL). Methods: Three hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL. Results: Expression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts. Conclusions: The validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies. Impact: Salivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects. Cancer Epidemiol Biomarkers Prev; 21(4); 664–72. ©2012 AACR.
Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL). Three hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL. Expression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts. The validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies. Salivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects.
Author Le, Anh
Xiao, Hua
Lingen, Mark
Kastratovic, Dragana A.
Henson, Bradley
Wang, Jianghua
Reiss, Jean
Zhou, Hui
Abemayor, Elliot
Chia, David
Morris, Darly
Hu, Shen
Wong, David T.W.
Randolph, Timothy
Feng, Ziding
Messadi, Diana
Wang, Marilene
Arellano, Martha
Nabili, Vishad
Sinha, Uttam
Elashoff, David
Akin, David
Author_xml – sequence: 1
  givenname: David
  surname: Elashoff
  fullname: Elashoff, David
– sequence: 2
  givenname: Hui
  surname: Zhou
  fullname: Zhou, Hui
– sequence: 3
  givenname: Jean
  surname: Reiss
  fullname: Reiss, Jean
– sequence: 4
  givenname: Jianghua
  surname: Wang
  fullname: Wang, Jianghua
– sequence: 5
  givenname: Hua
  surname: Xiao
  fullname: Xiao, Hua
– sequence: 6
  givenname: Bradley
  surname: Henson
  fullname: Henson, Bradley
– sequence: 7
  givenname: Shen
  surname: Hu
  fullname: Hu, Shen
– sequence: 8
  givenname: Martha
  surname: Arellano
  fullname: Arellano, Martha
– sequence: 9
  givenname: Uttam
  surname: Sinha
  fullname: Sinha, Uttam
– sequence: 10
  givenname: Anh
  surname: Le
  fullname: Le, Anh
– sequence: 11
  givenname: Diana
  surname: Messadi
  fullname: Messadi, Diana
– sequence: 12
  givenname: Marilene
  surname: Wang
  fullname: Wang, Marilene
– sequence: 13
  givenname: Vishad
  surname: Nabili
  fullname: Nabili, Vishad
– sequence: 14
  givenname: Mark
  surname: Lingen
  fullname: Lingen, Mark
– sequence: 15
  givenname: Darly
  surname: Morris
  fullname: Morris, Darly
– sequence: 16
  givenname: Timothy
  surname: Randolph
  fullname: Randolph, Timothy
– sequence: 17
  givenname: Ziding
  surname: Feng
  fullname: Feng, Ziding
– sequence: 18
  givenname: David
  surname: Akin
  fullname: Akin, David
– sequence: 19
  givenname: Dragana A.
  surname: Kastratovic
  fullname: Kastratovic, Dragana A.
– sequence: 20
  givenname: David
  surname: Chia
  fullname: Chia, David
– sequence: 21
  givenname: Elliot
  surname: Abemayor
  fullname: Abemayor, Elliot
– sequence: 22
  givenname: David T.W.
  surname: Wong
  fullname: Wong, David T.W.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25777198$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/22301830$$D View this record in MEDLINE/PubMed
BookMark eNp9kV1LwzAYhYNM3Kb-BKU34lVn0iRNgyDonDoYbKBehzRNINo1M-kG-_embkPwwqt88Jw3OecMQa9xjQbgAsERQrS4QZDSlPOcjiaLaYpQiiDHR2CAKC5Sxijtxf2B6YNhCB8QQsYpPQH9LMMQFRgOwN3C642sbSVb65rEmeQ1njbSb5MH65bSf2ofEuN8MveyTsayUdonj7rVqhOcgWMj66DP9-speH-avI1f0tn8eTq-n6WKUNSmZVllmBnGCGZEc5izjLBKac6R4hoxrTAvuWKGqPj9sjJcZSaTeVYiGCdIfAqud3NX3n2tdWjF0gal61o22q2D4DkmHHNCInm5J9flUldi5W10sRUHyxG42gMyKFkbHy3Z8MtRxhjiReRud5zyLgSvjVC2_Ump9dLWAkHRFSG6kEUXsohFxCvRFRHV9I_68MD_um8Gf4qa
CODEN CEBPE4
CitedBy_id crossref_primary_10_2174_0118715257269271231201094946
crossref_primary_10_3390_diagnostics11071287
crossref_primary_10_3390_ijms252413514
crossref_primary_10_1254_fpj_141_302
crossref_primary_10_3390_cancers12082273
crossref_primary_10_1002_jcb_26042
crossref_primary_10_1186_gm383
crossref_primary_10_2341_12_143_BL
crossref_primary_10_3892_ol_2018_9168
crossref_primary_10_1186_s13027_016_0093_6
crossref_primary_10_1016_j_oraloncology_2015_06_010
crossref_primary_10_1016_j_jebdp_2013_10_006
crossref_primary_10_1007_s00784_015_1488_2
crossref_primary_10_1136_flgastro_2016_100712
crossref_primary_10_1002_pmic_201200533
crossref_primary_10_1016_j_ajoms_2021_02_003
crossref_primary_10_1111_jog_13576
crossref_primary_10_3390_ma12040654
crossref_primary_10_14219_jada_archive_2012_0339
crossref_primary_10_1016_j_clinthera_2015_02_017
crossref_primary_10_1016_j_aca_2020_03_043
crossref_primary_10_1002_jbio_201500204
crossref_primary_10_1080_03610926_2018_1433849
crossref_primary_10_1016_j_archoralbio_2017_12_003
crossref_primary_10_14219_jada_archive_2012_0340
crossref_primary_10_1615_CritRevOncog_2022047079
crossref_primary_10_2116_analsci_31_73
crossref_primary_10_1016_j_jobcr_2015_08_006
crossref_primary_10_1080_14737159_2018_1523008
crossref_primary_10_1155_2013_813756
crossref_primary_10_1080_01635581_2018_1521439
crossref_primary_10_18231_j_jdp_2023_002
crossref_primary_10_4137_BIC_S25375
crossref_primary_10_3390_cancers6031522
crossref_primary_10_1016_j_oraloncology_2015_08_015
crossref_primary_10_1016_j_canep_2016_04_011
crossref_primary_10_1177_0022034513487209
crossref_primary_10_3390_cells12141916
crossref_primary_10_12688_f1000research_22941_1
crossref_primary_10_1186_1471_2288_14_37
crossref_primary_10_1002_hed_26526
crossref_primary_10_1111_jop_13299
crossref_primary_10_1038_nrclinonc_2012_20
crossref_primary_10_3390_diagnostics10100818
crossref_primary_10_1177_1559827615569707
crossref_primary_10_1080_14737159_2024_2340997
crossref_primary_10_1016_j_oor_2024_100503
crossref_primary_10_1016_j_oraloncology_2020_104720
crossref_primary_10_2217_bmm_2021_0370
crossref_primary_10_1016_j_oraloncology_2017_05_016
crossref_primary_10_1186_s12903_024_04840_3
crossref_primary_10_3109_07357907_2015_1041642
crossref_primary_10_1016_j_oraloncology_2014_09_005
crossref_primary_10_1111_joor_12664
crossref_primary_10_5507_bp_2016_062
crossref_primary_10_1096_fj_201600984R
crossref_primary_10_1177_1179299X17732007
crossref_primary_10_1016_j_bios_2021_113698
crossref_primary_10_3390_ijms16048676
crossref_primary_10_1016_j_bios_2016_02_040
crossref_primary_10_5125_jkaoms_2020_46_5_301
crossref_primary_10_1016_j_oraloncology_2015_10_007
crossref_primary_10_17656_sdj_10067
crossref_primary_10_1371_journal_pone_0177282
crossref_primary_10_3390_biomedicines12061150
crossref_primary_10_1038_s41598_024_75735_0
crossref_primary_10_1186_s12943_019_1021_3
crossref_primary_10_1038_srep31520
crossref_primary_10_1016_j_oraloncology_2016_07_013
crossref_primary_10_1146_annurev_anchem_061020_123959
crossref_primary_10_4236_abb_2020_115015
crossref_primary_10_3389_fpubh_2017_00077
crossref_primary_10_1002_cncr_27700
crossref_primary_10_1007_s00784_013_1041_0
crossref_primary_10_1016_j_bios_2021_112995
crossref_primary_10_1186_s13046_023_02743_9
crossref_primary_10_7717_peerj_12715
crossref_primary_10_1007_s12663_024_02365_4
crossref_primary_10_3389_fonc_2022_828434
crossref_primary_10_1002_med_21646
crossref_primary_10_1080_14737159_2017_1404906
crossref_primary_10_1038_s41598_020_64494_3
crossref_primary_10_1007_s40496_014_0014_y
crossref_primary_10_2144_000114254
crossref_primary_10_1016_j_humimm_2014_11_002
crossref_primary_10_1016_j_bj_2023_04_002
crossref_primary_10_1111_jop_12895
crossref_primary_10_1111_prd_12099
crossref_primary_10_1111_jre_12407
crossref_primary_10_1007_s11033_020_05659_1
crossref_primary_10_1021_acs_analchem_1c00410
crossref_primary_10_1074_jbc_M115_692640
crossref_primary_10_1021_pr500038k
crossref_primary_10_4103_jms_jms_90_23
crossref_primary_10_1016_j_urolonc_2016_12_007
crossref_primary_10_1002_sim_6811
crossref_primary_10_1016_j_ijom_2017_09_016
crossref_primary_10_1016_j_bcp_2013_08_026
crossref_primary_10_3109_00016357_2015_1110249
crossref_primary_10_4103_0973_029X_325237
crossref_primary_10_1371_journal_pone_0158462
crossref_primary_10_1007_s12253_017_0296_1
crossref_primary_10_1089_omi_2015_0174
crossref_primary_10_1097_MOO_0000000000000502
crossref_primary_10_1186_s12885_021_07932_3
crossref_primary_10_1186_2001_1326_3_3
crossref_primary_10_1158_1078_0432_CCR_15_1761
crossref_primary_10_5402_2012_931301
crossref_primary_10_1016_j_job_2014_06_001
crossref_primary_10_3390_ijms241713657
crossref_primary_10_18231_j_jdpo_2024_016
crossref_primary_10_1186_s13063_015_0951_3
crossref_primary_10_18632_oncotarget_4181
crossref_primary_10_1016_j_oooo_2016_08_021
crossref_primary_10_3390_ijms251910596
crossref_primary_10_1080_01478885_2020_1861918
crossref_primary_10_1158_1940_6207_CAPR_15_0200
crossref_primary_10_1111_jop_13003
crossref_primary_10_3390_cancers12082009
crossref_primary_10_1038_s41368_022_00209_w
crossref_primary_10_1373_clinchem_2018_290569
crossref_primary_10_1002_hed_24958
crossref_primary_10_1177_1535370216681550
crossref_primary_10_1186_s12957_021_02423_y
Cites_doi 10.1002/ijc.22369
10.1002/jcb.20784
10.1002/hed.20392
10.1002/pmic.200401133
10.1373/clinchem.2007.096164
10.1158/1078-0432.CCR-06-2945
10.1002/art.22954
10.1093/jnci/djn326
10.1158/1078-0432.CCR-05-2412
10.1158/1055-9965.EPI-04-0546
10.1158/1078-0432.CCR-04-1167
10.14219/jada.archive.2010.0223
10.1158/1078-0432.CCR-07-5037
10.1371/journal.pone.0005875
10.1016/j.jprot.2008.04.004
10.1177/154405910408300303
10.1373/49.1.1
ContentType Journal Article
Copyright 2015 INIST-CNRS
2012 AACR.
Copyright_xml – notice: 2015 INIST-CNRS
– notice: 2012 AACR.
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1158/1055-9965.EPI-11-1093
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1538-7755
EndPage 672
ExternalDocumentID 22301830
25777198
10_1158_1055_9965_EPI_11_1093
Genre Comparative Study
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations Los Angeles
GeographicLocations_xml – name: Los Angeles
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P30 CA015704
– fundername: NCI NIH HHS
  grantid: R21 CA126733
– fundername: NIDCR NIH HHS
  grantid: U01 DE016275
– fundername: NIDCR NIH HHS
  grantid: R01 DE017170
– fundername: NCI NIH HHS
  grantid: R21CA126733
– fundername: NIDCR NIH HHS
  grantid: U01DE016275
– fundername: NIDCR NIH HHS
  grantid: R01DE017170
GroupedDBID ---
18M
29B
2FS
2WC
34G
39C
53G
5GY
5VS
6J9
AAFWJ
AAYXX
ABOCM
ACPRK
ADBBV
ADCOW
AENEX
AFHIN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BR6
BTFSW
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
H13
IH2
KQ8
L7B
OK1
P2P
PQQKQ
QTD
RCR
RHI
SJN
UDS
W8F
WOQ
.55
3O-
AI.
C1A
H~9
IQODW
VH1
WHG
X7M
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c451t-bbd237f774374e9067247dce991c9e17ec39b9c7f4c538bdf9c2f2a62b10c45a3
ISSN 1055-9965
1538-7755
IngestDate Fri Jul 11 06:39:14 EDT 2025
Mon Jul 21 06:06:23 EDT 2025
Mon Jul 21 09:16:26 EDT 2025
Tue Jul 01 04:31:24 EDT 2025
Thu Apr 24 23:01:40 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Oral cancer
Stomatology
Biological marker
Biological indicator
Malignant tumor
Oral cavity
Salivary gland disease
Cancerology
Salivary gland cancer
Oral cavity disease
Diagnosis
Detection
Cancer
Language English
License CC BY 4.0
2012 AACR.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c451t-bbd237f774374e9067247dce991c9e17ec39b9c7f4c538bdf9c2f2a62b10c45a3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://aacrjournals.org/cebp/article-pdf/21/4/664/2275033/664.pdf
PMID 22301830
PQID 963493944
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_963493944
pubmed_primary_22301830
pascalfrancis_primary_25777198
crossref_citationtrail_10_1158_1055_9965_EPI_11_1093
crossref_primary_10_1158_1055_9965_EPI_11_1093
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-04-01
PublicationDateYYYYMMDD 2012-04-01
PublicationDate_xml – month: 04
  year: 2012
  text: 2012-04-01
  day: 01
PublicationDecade 2010
PublicationPlace Philadelphia, PA
PublicationPlace_xml – name: Philadelphia, PA
– name: United States
PublicationTitle Cancer epidemiology, biomarkers & prevention
PublicationTitleAlternate Cancer Epidemiol Biomarkers Prev
PublicationYear 2012
Publisher American Association for Cancer Research
Publisher_xml – name: American Association for Cancer Research
References Hu (2022060920125095100_bib11) 2007; 56
Bossuyt (2022060920125095100_bib19) 2003; 49
Franzmann (2022060920125095100_bib3) 2005; 14
Gao (2022060920125095100_bib20) 2009; 4
Houali (2022060920125095100_bib4) 2007; 13
Ulmer (2022060920125095100_bib14) 2006; 98
Li (2022060920125095100_bib12) 2004; 83
Cooper (2022060920125095100_bib18) 1994
Dowling (2022060920125095100_bib2) 2008; 71
Spafford (2022060920125095100_bib9) 2001; 7
Park (2022060920125095100_bib15) 2007; 120
Li (2022060920125095100_bib7) 2004; 10
Hu (2022060920125095100_bib13) 2008; 54
Rosas (2022060920125095100_bib8) 2001; 61
Franzmann (2022060920125095100_bib10) 2006; 28
Pepe (2022060920125095100_bib21) 2008; 100
Hu (2022060920125095100_bib5) 2008; 14
Rethman (2022060920125095100_bib1) 2010; 141
Marchetti (2022060920125095100_bib16) 2002; 62
Wu (2022060920125095100_bib17) 2005; 5
Nagler (2022060920125095100_bib6) 2006; 12
References_xml – volume: 61
  start-page: 939
  year: 2001
  ident: 2022060920125095100_bib8
  article-title: Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients
  publication-title: Cancer Res
– volume: 120
  start-page: 813
  year: 2007
  ident: 2022060920125095100_bib15
  article-title: Up-regulation of Mac-2 binding protein by hTERT in gastric cancer.
  publication-title: Int J Cancer
  doi: 10.1002/ijc.22369
– volume: 98
  start-page: 1351
  year: 2006
  ident: 2022060920125095100_bib14
  article-title: Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.20784
– volume: 28
  start-page: 663
  year: 2006
  ident: 2022060920125095100_bib10
  article-title: Complete hypopharyngeal obstruction by mucosal adhesions: a complication of intensive chemoradiation for advanced head and neck cancer
  publication-title: Head Neck
  doi: 10.1002/hed.20392
– volume: 7
  start-page: 607
  year: 2001
  ident: 2022060920125095100_bib9
  article-title: Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis
  publication-title: Clin Cancer Res
– volume: 5
  start-page: 3173
  year: 2005
  ident: 2022060920125095100_bib17
  article-title: Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model
  publication-title: Proteomics
  doi: 10.1002/pmic.200401133
– volume: 54
  start-page: 824
  year: 2008
  ident: 2022060920125095100_bib13
  article-title: DTW Exon-level expression profiling: a comprehensive transcriptome analysis of oral fluids
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2007.096164
– volume: 13
  start-page: 4993
  year: 2007
  ident: 2022060920125095100_bib4
  article-title: A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-2945
– volume: 62
  start-page: 2535
  year: 2002
  ident: 2022060920125095100_bib16
  article-title: Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients
  publication-title: Cancer Res
– volume: 56
  start-page: 3588
  year: 2007
  ident: 2022060920125095100_bib11
  article-title: Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome
  publication-title: Arthritis Rheum
  doi: 10.1002/art.22954
– year: 1994
  ident: 2022060920125095100_bib18
  article-title: The handbook of research synthesis
– volume: 100
  start-page: 1432
  year: 2008
  ident: 2022060920125095100_bib21
  article-title: Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djn326
– volume: 12
  start-page: 3979
  year: 2006
  ident: 2022060920125095100_bib6
  article-title: Concomitant analysis of salivary tumor markers–a new diagnostic tool for oral cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-2412
– volume: 14
  start-page: 735
  year: 2005
  ident: 2022060920125095100_bib3
  article-title: Salivary soluble CD44: a potential molecular marker for head and neck cancer
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-04-0546
– volume: 10
  start-page: 8442
  year: 2004
  ident: 2022060920125095100_bib7
  article-title: Salivary transcriptome diagnostics for oral cancer detection
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1167
– volume: 141
  start-page: 509
  year: 2010
  ident: 2022060920125095100_bib1
  article-title: Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas
  publication-title: J Am Dent Assoc
  doi: 10.14219/jada.archive.2010.0223
– volume: 14
  start-page: 6246
  year: 2008
  ident: 2022060920125095100_bib5
  article-title: Salivary proteomics for oral cancer biomarker discovery
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-5037
– volume: 4
  start-page: e5875
  year: 2009
  ident: 2022060920125095100_bib20
  article-title: Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0005875
– volume: 71
  start-page: 168
  year: 2008
  ident: 2022060920125095100_bib2
  article-title: Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumour progression and metastasis
  publication-title: J Proteomics
  doi: 10.1016/j.jprot.2008.04.004
– volume: 83
  start-page: 199
  year: 2004
  ident: 2022060920125095100_bib12
  article-title: RNA profiling of cell-free saliva using microarray technology
  publication-title: J Dent Res
  doi: 10.1177/154405910408300303
– volume: 49
  start-page: 1
  year: 2003
  ident: 2022060920125095100_bib19
  article-title: Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy
  publication-title: Clin Chem
  doi: 10.1373/49.1.1
SSID ssj0007955
Score 2.4511538
Snippet Background: Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early...
Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 664
SubjectTerms Adult
Aged
Biological and medical sciences
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Carcinoma, Squamous Cell - diagnosis
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - metabolism
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Feasibility Studies
Female
Follow-Up Studies
Genotype
Humans
Interleukin-8 - metabolism
Los Angeles
Male
Medical sciences
Middle Aged
Mouth Neoplasms - diagnosis
Mouth Neoplasms - genetics
Mouth Neoplasms - metabolism
Neoplasm Proteins - metabolism
Otorhinolaryngology. Stomatology
Prognosis
Real-Time Polymerase Chain Reaction
Retrospective Studies
RNA, Messenger - genetics
Saliva - chemistry
Tumors
Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology
Title Prevalidation of Salivary Biomarkers for Oral Cancer Detection
URI https://www.ncbi.nlm.nih.gov/pubmed/22301830
https://www.proquest.com/docview/963493944
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Ja9wwFBbTFEqhhO6dLkGH3oqnY1u2rEuhhJQ00I0mNDcjyXITSOxhxj60P6G_Ou9JGtnTpkt6MYMHPRu9z2_R2wh5HmO5ZFFlEU9rHjGdiEhJmYCXUkilagFWrM3yfZ_vH7GD4-x4MvkxylrqOzXT3y-tK_kfrsI94CtWyV6Bs4Eo3IDfwF-4Aofh-k88xv5LYEdXwez7LDGys_yGIybPMfFmadstvPiAZfi7yOAlSJjOpl81Y7vU_2eGebF289VABiGy8P2e2lHKh1ydtK6z4yg9Hg-i296qtf40xHTM6cpXjw2Q_OLPqw8Apl9Pejk-hcB0jpC84gTnPMsi8J1chNoMwpRz14Z3LW2TeIQqNhKduetm7rVw7gb6_Crgs8KeNfinzfY-vo1sUp6bs7jZUPsnRRfSD63jkxUlkimRTAlk4BaG49Nr5HrCwQ7DAP-nofM8F3aCbniyrwYDMi8vfZsNO-fWQq7gk6vdrJTfOzPWqDm8Tba9N0JfO2jdIRPT3CU33vl8i3vk1QbCaFvTNcLogDAKCKOIMOpQRAPC7pOjN3uHu_uRn7gRaZbFXaRUlaS8Bpcg5cwIDNMzXmkDToQWJuZGp0IJzWumgbeqqoVO6kTmiYrnQEGmD8hW0zbmEaHzCkcLqFTHPGZZLSR4xkVVKK3AhE91PiVsvT-l9u3ocSrKWflH7kzJLCxbuH4sf1uws7H5YRXoKs5jUUwJXXOjBNGK8TLZmLZflaCbmMDC8Sl56Lg0LAbPHZTh_PFVX-cJuTl8Pk_JVrfszTMwazu1Y_F2AaN0mUU
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalidation+of+Salivary+Biomarkers+for+Oral+Cancer+Detection&rft.jtitle=Cancer+epidemiology%2C+biomarkers+%26+prevention&rft.au=Elashoff%2C+David&rft.au=Zhou%2C+Hui&rft.au=Reiss%2C+Jean&rft.au=Wang%2C+Jianghua&rft.date=2012-04-01&rft.issn=1055-9965&rft.eissn=1538-7755&rft.volume=21&rft.issue=4&rft.spage=664&rft.epage=672&rft_id=info:doi/10.1158%2F1055-9965.EPI-11-1093&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1055_9965_EPI_11_1093
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1055-9965&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1055-9965&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1055-9965&client=summon